Targeted Genetics presents advances in synthetic gene delivery te...( Genetics' ability to develop novel and...)

Genetics' ability to develop novel and proprietary vectors, such as LPD, is one of the reasons we selected the company as our exclusive partner in gene delivery. Emerald Gene Systems will combine Elan's targeting technologies and Targeted Genetics' expertise in vector development and manufacturing to produce a new generation of therapeutics. We are pleased to be working with the leader in gene delivery and look forward to continuing our productive collaboration."

Background on LPD Targeted Genetics, in collaboration with Dr. Leaf Huang of the University of Pittsburgh, is developing a series of improved synthetic delivery systems based on various formulations of cationic lipids. In one of these systems, designated "LPD" for lipid-polycation-DNA, the DNA is condensed through the addition of a polycation to form small, degradation resistant cores encapsulated in a lipid shell. The resulting LPD formulation contains particles of defined size, which have enhanced stability and gene transfer efficiency. Pre-clinical experiments in non-tumor bearing mice have shown that the LPD system is able to deliver genes systemically through intravenous administration.

tgDCC-E1A Clinical Trial Background Targeted Genetics' Phase I trials of tgDCC-E1A in 36 breast, ovarian and head and neck cancer patients were completed in 1998. Dose-limiting toxicities were observed only in patients with ovarian cancer who received the highest doses of tgDCC-E1A by intraperitoneal infusion; however, subsequent changes to the procedure for making the final patient preparation are expected to reduce these toxicities in future trials. E1A gene transfer was detected in tumor samples from these patients in 15 of 15 patients tested. Eleven of 16 evaluable patients with head and neck cancer or breast cancer exhibited stable disease or some shrinkage of tumor. Reduced levels of HER-2/neu, a protein which is made by a cancer causing gene, was obser
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
8-Dec-1999

Page: 1 2 3 4 5
Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents clinical data on E1A cancer gene therapy
8. Targeted Genetics presents advances in systemic gene delivery technology
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin